Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

BACKGROUND: Long-term prophylaxis with subcutaneous C1-inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) in patients with hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE) was evaluated in an open-label extension follow-up study to the international, double-blind, placebo-controlled COMP...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Orphanet J Rare Dis
المؤلفون الرئيسيون: Lumry, William R., Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Anderson, John, Banerji, Aleena, Bernstein, Jonathan A., Caballero, Teresa, Farkas, Henriette, Gower, Richard G., Keith, Paul K., Levy, Donald S., Li, H. Henry, Magerl, Markus, Manning, Michael, Riedl, Marc A., Lawo, John-Philip, Prusty, Subhransu, Machnig, Thomas, Longhurst, Hilary
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2021
الموضوعات:
Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7885603/
https://ncbi.nlm.nih.gov/pubmed/33588897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-020-01658-4
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة